Weekly in Asia|Nov
20191117-1123 Innovative PD-1 Inhibitor Tyvyt® (Sintilimab) Now Included in the New Catalogue of National Reimbursement Drug List (NRDL) On November 28, Innovent Biologics, Inc. and Eli Lilly and Company jointly …
Read MoreThe Next Generation Biotech Media
20191117-1123 Innovative PD-1 Inhibitor Tyvyt® (Sintilimab) Now Included in the New Catalogue of National Reimbursement Drug List (NRDL) On November 28, Innovent Biologics, Inc. and Eli Lilly and Company jointly …
Read MoreAmarin, a pharmaceutical company developing therapeutics to improve cardiovascular health, and its latest product Vascepa approaches an approval for expanding the application of the treatment of cardiovascular (CV) patients to …
Read More20191117-1123 Japan Grants Orphan Drug Designation to Merck’s investigational therapy Tepotinib According to estimations, the incidence of cancer has increased at a rapid pace and hence, it has ascended to …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. Alnylam Pharmaceutical’s GIVLAARI™ (givosiran) became the second-ever RNA interference-based drug to bag the FDA nod. The RNA interference (RNAi) phenomenon discovered by Andrew Fire and …
Read More20191110-1116 I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China On November 14, I-Mab Biopharma, a China and U.S.-based clinical-stage …
Read MoreAlthough modern understandings of illness often suggest that being sick is synonymous with an inability to perform everyday tasks without help, research has proven that patients suffering from different ailments …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. Researchers isolate a novel heat resistant Cas9 nuclease from a hyperthermophilic bacterium that grows in a high-temperature environment. The CRISPR-Cas9 genome-editing tool has evolved rapidly …
Read More20191103-1109 Samsung Bioepis, Biogen to Commercialize Next-Generation Biosimilar Candidates South Korea based Samsung Bioepis Co., Ltd. announced on November 6 that the company has entered into a new commercialization agreement …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. Reblozyl, became the first and only erythroid maturation agent to be FDA approved for the treatment of anemia in adults with beta thalassemia who require …
Read MoreAbout Dr. Durhane Wong-Rieger Dr. Durhane Wong-Rieger, the founder of the Canadian Organization for Rare Disorders (CORD), is an educator and advocator of medical and social improvements for patients living …
Read More